Johnson & Johnson (JNJ) Shares Bought by Stock Yards Bank & Trust Co.

Stock Yards Bank & Trust Co. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 5.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 135,744 shares of the company’s stock after buying an additional 7,347 shares during the quarter. Johnson & Johnson makes up about 2.2% of Stock Yards Bank & Trust Co.’s investment portfolio, making the stock its 7th largest holding. Stock Yards Bank & Trust Co.’s holdings in Johnson & Johnson were worth $17,957,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Moreno Evelyn V lifted its holdings in Johnson & Johnson by 13.8% in the 1st quarter. Moreno Evelyn V now owns 59,068 shares of the company’s stock worth $7,356,000 after buying an additional 7,165 shares during the period. Chevy Chase Trust Holdings Inc. raised its position in shares of Johnson & Johnson by 0.8% in the 1st quarter. Chevy Chase Trust Holdings Inc. now owns 2,709,008 shares of the company’s stock worth $337,406,000 after acquiring an additional 21,762 shares in the last quarter. Curbstone Financial Management Corp raised its position in shares of Johnson & Johnson by 6.4% in the 1st quarter. Curbstone Financial Management Corp now owns 15,326 shares of the company’s stock worth $1,909,000 after acquiring an additional 925 shares in the last quarter. Pioneer Trust Bank N A OR raised its position in shares of Johnson & Johnson by 0.6% in the 1st quarter. Pioneer Trust Bank N A OR now owns 34,269 shares of the company’s stock worth $4,268,000 after acquiring an additional 211 shares in the last quarter. Finally, Peachtree Investment Advisors Inc. raised its position in shares of Johnson & Johnson by 0.7% in the 1st quarter. Peachtree Investment Advisors Inc. now owns 22,138 shares of the company’s stock worth $2,757,000 after acquiring an additional 160 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

Johnson & Johnson (NYSE:JNJ) traded down 0.66% during mid-day trading on Thursday, hitting $132.34. The company’s stock had a trading volume of 1,733,646 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The firm’s 50-day moving average is $132.79 and its 200-day moving average is $129.43. The company has a market cap of $355.20 billion, a P/E ratio of 22.39 and a beta of 0.79. Johnson & Johnson also saw unusually large options trading on Wednesday. Traders acquired 11,192 put options on the company. This represents an increase of approximately 244% compared to the average daily volume of 3,249 put options.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. Johnson & Johnson’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.74 earnings per share. Analysts predict that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.84 per share. The ex-dividend date was Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://sportsperspectives.com/2017/09/21/johnson-johnson-jnj-shares-bought-by-stock-yards-bank-trust-co.html.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

Several research analysts have recently issued reports on the company. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Atlantic Securities lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 target price for the company. in a research report on Friday, July 21st. BTIG Research lowered Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price for the company. in a research report on Friday, July 21st. Alembic Global Advisors lowered Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research report on Friday, July 21st. Finally, Vetr lowered Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research report on Monday. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $135.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply